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Abstract
Background: Prisons are a key location to access Hepatitis C Virus (HCV) infected people who inject drugs (PWID).
Prison health care structures are complex and optimising health care delivery to this high need, marginalised and
underserved population remains challenging. Despite international guidelines recommending that prisons are a
priority location for HCV screening and treatment levels of prisoner engagement in HCV care remain low.
Competing priorities between security and healthcare is a key feature of prison health care. A collaborative
approach to health care delivery in prisons can maximise the benefits for prisoners, staff and the wider community.
Aim: To identify the barriers and enablers to HCV screening and treatment in Irish prisons and inform the
implementation of a HCV screening program within the Irish Prison Services (IPS).
Methods: Qualitative study using focus group methodology underpinned by grounded theory.
Results: The following themes emerged from the analysis: priority of safety and security, staffing and resources,
concerns about personal risk, lack of knowledge, concerns around confidentiality, prisoners’ fear of treatment and
stigma, timing of screening, use of peer workers, in-reach hepatology and fibroscanning services. The primary role
of prison security is to ensure the safety of staff and prisoners with a secondary but important supporting role in
health care delivery. Maintaining adequate staffing levels and the provision of training and education were seen as
priorities and impacted on prison officers’ fear for personal safety and risk of HCV transmission. Opt-out screening
and peer support workers had high levels of support among participants.
Conclusion: Upscaling HCV management in prisons requires an in-depth understanding of all barriers and
facilitators to HCV screening and treatment. Engaging prison officers in the planning and delivery of health care
initiatives is a key strategy to optimising the public health opportunity that prisons provides.
Keywords: Hepatitis C virus, HCV, Prison, Prison officer, Governor, Screening, Treatment, Dual loyalty
Introduction
Hepatitis C Virus (HCV) infection is a leading cause of liver
related morbidity and mortality across Europe. An esti-
mated 14 million people are chronically infected with this
blood borne virus in the European region and over 70,000
dying annually from HCV related liver cirrhosis and cancer
(WHO 2017). Injecting drug use (IDU) is the major driver
of the HCV epidemic in developed countries and now
accounts for 80% of new infections in the European union
(Degenhardt et al. 2017; WHO 2017).
The incidence and prevalence of HCV infection is much
higher in people who inject drugs (PWID) than the gen-
eral population (Degenhardt et al. 2017; Nelson et al.
2011). It is estimated that over 50% of PWID globally have
chronic HCV infection (Nelson et al. 2011; WHO 2017).
Across Europe the prevalence of anti-HCV among PWID
ranges from 15%–84% with the average prevalence almost
50 times higher than the general population (WHO Eur-
ope 2015). Ongoing criminalisation of PWID ensures that
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they experience high rates of incarceration (56%–90%
ever being incarcerated) and previous incarceration is
associated frequently with HCV infection and in-
creased injecting risk in the community (Cepeda et al.
2015; Jürgens et al. 2011). Recent prison release is
also associated with heightened HCV transmission
risk which is particular concern since the majority of
prisoners globally (including Ireland) serve short
prison sentences (Binswanger et al. 2007; Irish Penal
Reform Trust 2018; Stone et al. 2017).
There are an estimated 3674 persons incarcerated
across 15 institutions in the Republic of Ireland (ROI)
on a daily basis (Irish Penal Reform Trust 2018). Irish
prisoners are some of the most marginalised people
in Irish society and despite having high rates of phys-
ical and psychiatric morbidity are underserved by
traditional health services (Allwright et al. 2000;
Drummond et al. 2014). They suffer high levels of
poverty, social deprivation, homelessness, early school
dropout, unemployment, illiteracy, mental illness and
drug use (Barry et al. 2010; Drummond et al. 2014).
Over half of Irish prisoners report a history of drug
use and 43% a history of IDU (Drummond et al.
2014). An estimated 13% of Irish prisoners have been
infected with HCV (Drummond et al. 2014). HCV
prevalence varies across Irish prison facilities and is
related to the number of PWID incarcerated at the
location (Allwright 2000; Drummond et al. 2014;
Long et al. 2001). National and international HCV
strategies and treatment guidelines identify prisoners
as a key population to screen and treat for HCV in-
fection yet uptake within prisons remain low (Depart-
ment of Health 2017; European Association for the
Study of the Liver 2017; European Monitoring Centre
for Drugs and Drugs Prevention 2016; Health Service
Executive 2012; Martin et al. 2015).
The availability of once daily, easy to tolerate,
highly effective pan-genotypic direct acting anti-virals
(DAA), mobile elastography for liver disease assess-
ment and less restrictive treatment guidelines has
revolutionised HCV management (Crowley et al.
2017; European Association for the Study of the Liver
2017; Grebely et al. 2017). HCV infection is a curable
and preventable disease and the World Health Organ-
isation (WHO) have declared its elimination by 2030
a public health goal (WHO 2017). Despite this opti-
mism many challenges remain to engage high-risk
populations in HCV care. A number of studies have
identified prisoner and nurse reported barriers to
HCV management in prison settings including: con-
cerns regarding stigma and discrimination, lack of in-
formation regarding screening procedures, fear of
treatment, competing priorities and short prison sen-
tence and inter-prison transfer (Khaw et al. 2007; Yap
et al. 2014). Enablers to prison –based HCV care have
also been identified and these include: dried blood
spot testing, opt-out screening, in-reach hepatology,
tele-medicine, nurse-lead clinics and peer support
(Arora et al. 2007; Lloyd et al. 2013; Martin et al.
2013; Morris et al. 2017).
It is recognised that prison health care structures
are complex and the relationship between health care
workers and security staff can impact health care de-
livery (Fazel and Baillargeon 2011; Møller et al. 1936;
WHO 2014). The concept of dual loyalty has been
described in the literature which can create conflict
between health care professionals and security staff
(Pont et al. 2012). While the maintenance of security
and safety is the first priority for prison governors
and officers, they also play a crucial supportive role
in prison health care (Ismail and de Viggiani 2018).
Prison governors’ and officers’ views on health care
delivery are rarely reported in the literature. We only
found one study that explored prison officers’ views
on HCV screening and treatment published in the lit-
erature to date (Jack et al. 2017). This study aims to
explore prison governors’ and officers’ views on bar-
riers and enablers to HCV screening and treatment
which will inform the development of Irish public
health strategy to increase HCV screening and
treatment in prisoners nationally. It may also inform
international approaches to prison -based HCV man-
agement and increase awareness and knowledge about
the complex and important relationship that exists
between security and health care staff in prison and
how this can impact health care delivery.
Methodology
Five focus groups were conducted among two grades of
security staff: the prison governor (n = 3) and prison of-
ficer (n = 2). In the Irish prison system (IPS), the overall
security and operational issues for each prison is man-
aged by governors with prison officers responsible for
delivery of front-line services. Prison officers report to
governors. The governor component of the study is na-
tional in coverage and includes input form 13 of the 15
prisons in the ROI. Usually Governors have also worked
as prison officers in the earlier part of their careers. For
convenience and due to restricted access to other prison
locations, the prison officer focus groups were confined
to two Dublin prisons: Mountjoy male prison and the
Dochas female prison. Many of the prison officer partici-
pants had worked in many different prison locations
across the country and this experience is included in
their contribution to the study. The focus group meth-
odology was chosen to allow for the maximum number
of participants to contribute, its acceptability in a
real-life setting and to capture the richness, complexity
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and scope of the issues. Ethical approval was obtained
from the Mater Ethics Committee as part of the Seek
and Treat component of The European Hep Care Pro-
ject and supported and endorsed by the IPS ethics group
(Lambert et al. 2018).
Different recruitment strategies were used for differ-
ent focus groups. For the governor focus groups, invi-
tations were sent by email to all governors working in
the IPS. The focus groups were organised on days
and at times that coincided with national monthly
meetings to maximise attendance and minimise dis-
ruption. The recruitment of prison officers was by
open invitation, with times and dates of focus groups
advertised on local noticeboards, the electronic staff
communication system and word of mouth. Local
staff groups were conducted on-site in communal pri-
vate rooms deemed suitable by the research team.
National groups were conducted off-site and the Irish
Prison Service College (Stack House). Data collection
took place during a three-month period in 2017. All
participants were given a participant information
sheet (PIS) containing information on the study and
had opportunities to ask questions before giving their
informed written consent to participate.
Following a review of the published literature on the
topic, completion of a scoping review and consultation
with the research group and national experts in the area
a focus group guide was finalised. This guideline in-
cluded a series of open ended questions covering the fol-
lowing areas; experience of prison healthcare delivery
including HCV screening and treatment, barriers and
enablers to prisoners’ engagement with prison-based
HCV care, challenges related to incarceration and re-
lease, inter-prison variations in health care and the role
of prison officers and peers in prison HCV management.
Each group was moderated and observed by two re-
searchers from the research team. Focus group inter-
views were recorded using an encrypted digital audio
recorder, and observations of group dynamics and inter-
actions were written in field notes during and after the
event. After each focus group, audio recordings were
transcribed using Microsoft word and were uploaded
to NVIVO 11 for coding and thematic analysis. Inter-
view data were coded as collected and the topic
guides revised accordingly. A grounded theory ap-
proach informed both the collection and analysis of
the data. The thematic coding was revised with the
analysis of each focus group and analysis ceased when
thematic saturation was achieved (agreed by re-
searcher 1 and 2).
Results
Five focus groups were conducted involving a total of 68
participants. Seven females were included in the study
which is a lower representation that expected given that
females represent 16% of prion officers and 30% of gov-
ernors in the IPS. The five focus groups produced 7.5 h
of narratives. The following themes emerged from the
analysis: priority of safety and security, staffing and re-
sources, concerns about personal risk, lack of know-
ledge, concerns around confidentiality, prisoners’ fear of
treatment and stigma, timing of screening, use of peer
workers, in-reach hepatology and fibroscanning services.
Priority of safety and security
All focus groups included discussions about issues of secur-
ity and safety in their prisons. While supportive and under-
standing of the benefits of prison health care their primary
focus was to ensure the safety of both staff and inmates.
Local prison officers spoke of the increased security
concerns related to protection of prisoners and how bur-
geoning gangland feuds and rival factions made their jobs
very difficult. This created barriers to both HCV screening
and treatment since it reduced face to face time with pris-
oners and medical staff because security staff are required
to accompany prisoners to medical appointments.
“Keeping our prisons secure is the first priority – that
is where we start every day”. (Governor)
“Supporting healthcare is important but we need to
ensure that staff are covering the landings first”.
(Governor)
“In some areas (of the prison) have trouble getting around,
takes half an hour, you can’t cut corners ...... if you turn
your back they ‘d kill each other” (Prison officer)
Staffing and resources
Safety and security concerns were closely underpinned
by lack of staff and resources. This was a persistent
theme throughout all narratives. Lack of custodial staff
impacted negatively on the delivery of health care.
“I think it’s … it’s looking at how you maximise
operations, .... the most efficient system in place and
how to support that. Whether it’s more officers or
nurses. There should be more supports in the prison
and resources should be going into the prison rather
than spending it on sending prisoners back and forth
to the hospital” (Governor)
“There has to be a plan. Has to be enough staff. People
who are trained” (Prison officer)
Hospital visits outside the prison were viewed as an inef-
ficient and resource heavy way of providing health care
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to prisoners. Minimising hospital visits by expanding in-
reach services (bringing specialist medical services into
the prison) were seen as facilitating prisoners’ access to
health care including HCV care.
“Anything that stops us going outside the main gate is
good”. (Governor)
Concerns about personal risk
A recurring theme throughout the prison officer focus
groups was concern for personal safety. This concern
covered the areas of personal safety and risk of
exposure to and acquisition of blood borne viruses
including HCV. Prison officers described a work en-
vironment of increasing inter-prisoner violence and
severity of assault often leading to open wounds and
blood loss.
“I worry about myself--------, with the increased
violence actually………, we are exposed more and more
to open wounds and stuff” (Prison officer)
“Our biggest one is blood to blood …. violence with
blood to blood contact that is the main one we
probably have here”. (Governor)
“Staff are still worried – they have families, children”.
(Prison officer)
Lack of knowledge
Lack of knowledge was recognised as a major barrier
to HCV screening and treatment. Participants identi-
fied the provision of education and training as a
means of addressing this knowledge deficit. All grades
of staff felt their lack knowledge in relation to the
newer HCV treatment and the risks of transmission
impacted on their ability to engage with prisoners on
this issue.
“Blood viruses are a big issue in our prisons ...staff
awareness must be brought forward as well, they have
to buy into it as well”. (Governor)
“Staff worry about HIV and HCV ... we need more
education programs and training for staff but it also
hard to release staff for training”. (Governor)
Participants also identified the lack of knowledge among
prisoners as a barrier to HCV treatment in particular
the inaccurate information being circulated regarding
the side effects of treatment which were historical and
associated with interferon-based treatment.
“…. a lot of prisoners don’t know what they have or
have been tested even if they are at high risk”. (Prison
officer)
“It’s patchy, the prisoner’s knowledge that we come
across .... they don’t really know how to access
treatment”. (Prison officer)
Concerns regarding confidentiality
Medical confidentiality was discussed in all groups and
it was acknowledged to be a prisoner right and an essen-
tial tenet underpinning health care delivery.
“Prisoners are concerned that we access records for
things like DNA ... we (custodial staff ) have no access
what so ever to PHMS (electronic patient record)”
(Governor)
Front line prison officer participants had a much more
nuanced discussion in relation to this topic with a ma-
jority reporting that lack of confidentiality was a barrier
to HCV screening and treatment. Often breaches in con-
fidentiality were inadvertent and were related to pris-
oners being called to attend certain clinics /doctors that
were connected with HCV, addiction treatment or HIV
care.
“It is difficult at times- when prisoners are called to
see the Hep (in-reach hepatology) nurse or the phy
(methadone) doctor ... why else would they be seeing
them”. (Prison officer)
Prison officers reported that some patients treated with
interferon-based therapies suffered significant side ef-
fects from treatment and these were so visible that both
staff and fellow prisoners knew that they were having
HCV treatment.
“Guys who’ve lost a lot of weight, often very noticeable
weight loss with previous treatments ……… common
knowledge among staff and prisoners that they are on a
course of Hep treatment” (Prison officer)
A number of participants described examples of prisoners
forgoing their privacy by openly discussing their health is-
sues with both non-clinical staff and fellow prisoners.
“Ah sure some of them don’t care who knows what
-----, they would come up to you and say here medic
can you get me an appointment” (Prison officer)
A number of officers felt that if issues regarding confi-
dentiality were addressed that more prisoners would
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approach prison officer to discuss HCV related concerns
and that this might be a resource to educate prisoners
on HCV related issues.
“I feel that they would come to me if things were a bit
more private” (Prison officer)
Prisoners’ fear of treatment and stigma
A number of participants identified fear of treatment
as a barrier to prisoners engaging with health ser-
vices. Fear of treatment was linked to: side effects of
interferon treatment, liver biopsy and the concerns
about stigma. Participants also identified that making
screening routine or opt-out, had the potential to re-
duce stigma.
“They won’t show up to the doctor because they’re
scared”. (Governor)
“In terms of history and patient issues, patients think
they’re going to get very sick on it (interferon), they
think they’re going to end up in a heap”. (Prison
officer)
“I hear them (prisoners) say “don’t get that liver
biopsy”, they’re still afraid ... word of mouth is a big
thing in the prison”. (Prison officer)
“Stigma – they have been dealing with that for years –
fear of HIV -body suit the works”. (Prison officer).
“We need to reduce the stigma – making it routine is
the way to go”. (Governor)
Time of screening
Both prison officer and governor participants favoured
a structured and systematic approach to HCV screen-
ing. The committal period was identified by all
groups as an opportune time to engage prisoners with
health services and provide HCV screening. Security
and health care staff are prioritised to cover the
committal process which is standardised and involves
the completion of an electronic nursing health
assessment.
“Committal is a good time to get them tested -----,
it’s always staffed, in fact you should make it
compulsory ----of course, unless they know their test
result already” (Prison officer)
“Big benefit is that if you know he needs treatment,
you can sort it straight away”. (Governor)
“Obviously the best time to do it is on committal, you
don’t want to go to pick them up a few weeks later and
it’s hard because the turnover is so big. You’d nearly be
starting again”. (Prison officer)
Many felt that screening should be compulsory on
committal with small numbers believing that it should
be voluntary.
“At the committal stage it should be compulsory”.
(Prison officer)
“It’d have to be voluntary”. (Governor)
Some prison officers identified other time periods that
might be suited to HCV screening. They described
“down times” within the week where routine work was
not scheduled. They also noted that health related pro-
grams provided during these times might have the added
benefit of relieving boredom for prisoners
“There are down times in here – Sunday after mass,
prisoners are bored and would get involved” (Prison
officer)
Peer workers
Participants in all focus groups agreed that trained
peer workers had the potential to facilitate prisoner
engagement with health services including HCV
screening and treatment. A number of participants
had engaged in the past with mass BBV and TB
screening initiatives with peer workers from the Irish
Red Cross. The narrative around peer workers in-
cluded prisoners having more trust in their peer net-
works than “The System”.
“Peer led education is better than say something
coming from the top down. Let the guys at the ground
work up.” (Governor)
“Peer to peer ……. .and it was very successful when we
did it the last time ……. using the volunteers, like we
did the last time, we got a 78 % buy in because of
that.” (Prison officer)
“They see us may be pulling the wool but if it came
from themselves ……. we’d be able to get over that
hurdle”. (Prison officer)
“They wouldn’t come up and talk to you
(prison officer). They’d be asking about getting
a blood test to each other. They wouldn’t
come to you”. (Prison officer)
Crowley et al. Health and Justice            (2018) 6:23 Page 5 of 10
In -reach hepatology and fibroscanning services
The availability of in-reach hepatology and mobile elasto-
graphy were seen as enablers to prisoner engagement in
HCV care. The cost –effectiveness and staff saving bene-
fits of in-reach services were viewed by the governor focus
groups as a major benefit. The reduction of risk associ-
ated with prisoners having to attend hospital services
was also noted. In-reach services and fibro-scanning
were seen as increasing the awareness of the HCV
disease among both prisoners and staff (Table 1).
“Anything that stops us going outside the main gate is
good”. (Governor)
“The in reach - raises the awareness ...... raises the
profile of the disease as a thing”. (Prison officer)
“Certainly, the awareness of the Hep C has gone up in
the last couple of months with the fibroscanner ... I see
more engagement with staff and prisoners”. (Governor)
Discussion
This study provides a unique insight into governors’ and
prison officers’ views on HCV screening and treatment
in Irish prisons. Many of the themes identified in this re-
search including: lack of knowledge, fear of treatment,
concerns regarding confidentiality and stigma as barriers
to HCV screening and treatment have been reported
previously in the literature (Jones et al. 2014; Swan et al.
2010). As outlined above the majority of available quali-
tative literature published on the topic of HCV in prison
is from the prisoners’ and health care staffs’ perspectives
(Khaw et al. 2007; Yap et al. 2014). This study identified
similar barriers from a security staff perspective and
found an unexpected level of knowledge and under-
standing of this research topic. The focus group narra-
tives demonstrate insight and empathy into the
complexity of prisoners’ health needs and illustrates the
struggle to provide health care to this group in an envir-
onment where prisoner and staff safety and security is
paramount.
Participants identified lack of knowledge regarding
HCV among prisoners as a concern. Health promotion
is a key aspect of prison health care (Møller et al. 2007;
Santora et al. 2014). Providing fact sheets on the man-
agement of chronic illnesses, including HCV, to pris-
oners is recommended by the WHO (Møller et al. 2007;
WHO 2014). These should be at an appropriate literacy
level and in different languages reflecting the demo-
graphic makeup of the prison population. Consideration
should also be given to the use of video for prisoners
with poor literacy skills (Møller et al. 2007). This study
identified lack of knowledge about BBV among security
staff as a concern. A number of studies have identified
this previously with one evaluating training packages to
address the issue (Dillon and Allwright 2005; Jack et al.
2017; Perrett et al. 2014). An e-learning package on
blood-borne viruses (BBV) piloted in a Welsh prison im-
proved staff understanding of BBV and the authors rec-
ommended that it be incorporated into prison staff
training (Perrett et al. 2014). Improving knowledge on
BBV among prison staff has the potential to alleviate fear
among staff but also to reduce the stigma experienced
by prisoners in relation to identification of their HCV/
HIV status and history of IDU (WHO 2014). The im-
portance of educating security staff about health prob-
lems affecting prisoners is a fundamental tenet
underpinning prison healthcare (Møller et al. 2007). It is
also important that all staff receive training on and
understand the complex ethical issues associated with
prison health care delivery including those linked to
HCV screening and treatment (Allen and Aburabi 2016;
Kelk 1999; Levy and Larney 2015; WHO 2014).
The issue of stigma experienced by PWID, prisoners
and HCV infected people as a barrier to engagement in
health services is commonly reported in the literature
(Ford and Bressan 2014; Golden et al. 2006; Swan et al.
2010; Yap et al. 2014). HCV infected prisoners are some
of the most marginalised people and their fear and ex-
perience of stigma impacts negatively on their engage-
ment with medical services (Fazel and Baillargeon 2011).
Stigma that is experienced is closely linked with con-
cerns regarding confidentiality. Security staff in Irish
Table 1 Summary of barriers and enablers to HCV screening and treatment in prisoners
Barriers Enablers
Increased security needs reduce allocated time for supporting medical services In-reach medical services reduce requirement for hospital visits
Inadequate staffing and resources Provision of education and training
Lack of knowledge about HCV among security staff and prisoners Reassuring prisoners regarding confidentiality
Misinformation regarding historical HCV treatments circulating among prisoners Opt-out HCV screening on committal
Concerns regarding medical confidentiality Utilisation of ‘down-time’ in the prison timetable
Prisoners’ fear of treatment side effects and liver biopsy Prison peer workers
Prisoners’ experience and fear of stigma On-site hepatology and Fibroscan
Crowley et al. Health and Justice            (2018) 6:23 Page 6 of 10
prisons identified this concern as a major block to pris-
oner engagement in HCV care and provided insights
into the complexity of the issue. Maintaining medical
confidentiality in prisons is problematic and can often
be broken by the types of services that prisoners engage
with while incarcerated (Allen and Aburabi 2016). Pris-
oners attending OST services will be identified as drug
users and those attending HIV/HCV in-reach services
will have their BBV status declared. Integrating HCV
treatment into the prison primary care system has the
potential to reduce stigma and protect medical confiden-
tiality (Read et al. 2017).
This study identified peer workers as an enabler to
prisoners engaging in HCV screening and treatment and
reducing stigma. The use of peer workers in community
HCV management is well documented (Arain et al.
2016; Harris and Rhodes 2013; Rhodes et al. 2013; Roose
et al. 2014; Treloar et al. 2014). Peer workers can dispel
the myths and fears associated with HCV treatment, re-
duce stigma, enhance mutual trust, enhance social sup-
port, and increase knowledge and engagement in HCV
care. Evidence supports the effectiveness of prison peer
workers at reducing risky behaviours, their acceptability
within the prison environment and their positive impact
on those that engage with the service (Bagnall et al.
2015; Broadhead et al. 2002; European Centre for Dis-
ease Prevention and Control 2018; Macarthur et al.
2016; South et al. 2014).
Prison settings are charcterised by high rates HCV in-
fection and risk behaviours, all of which can potentially
impact on staff safety (Larney et al. 2013; Vescio et al.
2008). Many prison officer participants reported feeling
concerned about their risk of work-related acquisition of
BBV. This concern was heightened by a growing culture
of gangland violence in Irish prisons, heightening pris-
oner related violent behavior whilst incarcerated (Irish
Penal Reform Trust 2018).
Implementing evidenced- based harm reduction
measures such as needle and syringe programs (NSP),
opioid substitution treatment (OST) and vaccination
against hepatitis B virus (HBV) can reduce BBV
transmission in prisons (Arain et al. 2014). Combined
with active case finding and treatment of HCV infec-
tion, it has the potential to eliminate HCV infection
in prison settings thus making this environment safer
for both prisoners and staff (Hajarizadeh et al. 2017;
Martin et al. 2015; World Health Organization 2015).
Micro-elimination of HCV infection has been re-
ported in some prisons and is increasingly being rec-
ommended as an effective HCV public health strategy
(Bartlett et al. 2018; Cuadrado et al. 2018; Lazarus et
al. 2017; Redman and Sterling 2018). It has the added
effect of making the work environment safer for se-
curity staff and may impact positively on their
engagement with public health strategies aimed and
HCV micro-elimination at an institutional level.
This study identifies the need for a structured and sys-
tematic approach to HCV screening in Irish prisons.
Opt-out screening on committal has previously been
shown to increase HCV care uptake in prisons and re-
duce stigma (European Centre for Disease Prevention
and Control 2018; Larney et al. 2014; Morris et al. 2017;
Rumble et al. 2015). However concerns have been
expressed about the ethical issues that may arise with in-
formed consent and the potential for coercion (Levy and
Larney 2015). Committal to prison is identified as stress-
ful for prisoners and HCV screening and treatment is
just one of many competing priorities at this time (Levy
and Larney 2015; Morris et al. 2017; Rumble et al. 2015).
This study identified that “down times” occurring in
prison life might provide an opportunity to engage pris-
oners that had refused opt-out HCV screening at
committal.
The use of focus group methodology allowed for a
large number of prison officers and governors to engage
with the study. It is a practical and acceptable way to
conduct research in real life prison settings. The inter-
action among participants during the group provided
the opportunity for an in-depth exploration of topics. A
further strength of this study is the national coverage of
the governor focus group and the engagement of prison
officers from both male and female prison locations.
Having prison officer representation from only two out
of the 15 prison locations is a limitation of the study. Re-
searcher 1 (DC) was known to most focus group partici-
pants which may have impacted on their willingness to
fully disclose their views in a positive way. The low
number of female participants was also seen as a limita-
tion. The recruitment by invite for the prison officer
focus groups may have biased the findings since only
those with an interest in the area of health care may
have participated. Demographics such as age, gender
and length of time in service were not collected since
these were deemed to be too sensitive to collect in a
work environment and so we cannot determine that
focus group participants were representative of the study
population.
Conclusion
Prisoners are from marginalised groups who are under-
served by traditional healthcare systems. Their time in
prison may offer a unique opportunity for the diagnosis,
assessment and treatment of HCV infection. Adapting a
whole prison approach to HCV screening and treatment
is essential to optimise uptake of HCV care. While the
maintenance of prison security is the primary function
of prison officers and governors, supporting prison
health care is an important role. Providing education
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around HCV screening and treatment to both prison
staff and prisoners has the potential to increase know-
ledge and reduce fear and stigma. Adopting opt-out
screening at committal is supported by both prison offi-
cers and governors and is an evidence-based approach
to increasing uptake of HCV care among prison popula-
tions. The use of peer workers in prison settings is also
supported by Irish prison security staff but its imple-
mentation needs to be underpinned by a robust manage-
ment and governance to ensure prison security is not
jeopardised. Understanding health care delivery and con-
cerns from a security staff perspective is crucial to opti-
mising the benefits of prison health care. Working
jointly towards HCV elimination in prison can have a
positive impact both on prisoner health and the prison
work environment.
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